Literature DB >> 19735100

DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters.

Qi-lian Liang1, Bi-rong Wang, Guo-hong Li.   

Abstract

OBJECTIVE: To investigate the expression of death decoy receptor 3 (DcR3) and survivin in colorectal carcinoma.
METHODS: Tumor and normal tissues were taken from a total of 100 colorectal carcinoma patients during surgery, and the expression of DcR3 and survivin was examined by immunohistochemistry, Western blotting, and reverse transcription-polymerase chain reaction (RT-PCR) analyses.
RESULTS: RT-PCR showed that the expression levels of DcR3 mRNA (0.846+/-0.242, P<0.01) and survivin mRNA (0.7835+/-0.2392, P<0.01) in colorectal cancer tissues were significantly higher than those in adjacent normal tissues. Western blotting showed that the expression levels of DcR3 protein (0.795+/-0.261, P<0.01) and survivin protein (0.6765+/-0.1351, P<0.01) in tumor tissues were significantly higher than those in non-cancer tissues. The immunohistochemical streptavidin-peroxidase (SP) method showed that the positive expression rates of DcR3 and survivin were 67.0% and 58.0% in colorectal cancer tissues, and 18.0% and 3.0% in non-cancerous colorectal tissues (P<0.05), respectively. The positive correlations of DcR3 (P<0.01) and survivin (P<0.01) to the differentiation of colorectal carcinoma cells, lymph node metastasis, and pathological stage were observed. The expression of DcR3 and survivin was found to be positively correlated to clinicopathologic parameters of colorectal carcinoma.
CONCLUSION: The overexpressed DcR3 and survivin in colorectal cancer may contribute to the development of the cancer. The monitoring of these two proteins may be useful for the diagnosis, differentiation, metastasis, and determination of stages of colorectal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19735100      PMCID: PMC2738837          DOI: 10.1631/jzus.B0920077

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  25 in total

1.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides.

Authors:  Chunyao Xia; Zhidong Xu; Xiaocheng Yuan; Kazutsugu Uematsu; Liang You; Kai Li; Li Li; Frank McCormick; David M Jablons
Journal:  Mol Cancer Ther       Date:  2002-07       Impact factor: 6.261

2.  Apoptosis resistance in ulcerative colitis: high expression of decoy receptors by lamina propria T cells.

Authors:  Raja Fayad; Marc I Brand; David Stone; Ali Keshavarzian; Liang Qiao
Journal:  Eur J Immunol       Date:  2006-08       Impact factor: 5.532

3.  Increased expression of soluble decoy receptor 3 in acutely inflamed intestinal epithelia.

Authors:  Sunghee Kim; Anastasia Fotiadu; Vassiliki Kotoula
Journal:  Clin Immunol       Date:  2005-06       Impact factor: 3.969

4.  Expression of survivin in human gastric carcinoma and gastric carcinoma model of rats.

Authors:  Xiao-Dong Zhu; Geng-Jin Lin; Li-Ping Qian; Zhong-Qing Chen
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

5.  Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.

Authors:  R M Pitti; S A Marsters; D A Lawrence; M Roy; F C Kischkel; P Dowd; A Huang; C J Donahue; S W Sherwood; D T Baldwin; P J Godowski; W I Wood; A L Gurney; K J Hillan; R L Cohen; A D Goddard; D Botstein; A Ashkenazi
Journal:  Nature       Date:  1998-12-17       Impact factor: 49.962

6.  [Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof].

Authors:  Hong-wei Shen; Yu-lian Wu; Shu-you Peng
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2003-05-10

7.  Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients.

Authors:  Yulian Wu; Bing Han; Hongwei Sheng; Min Lin; Paul A Moore; Jun Zhang; Jiangping Wu
Journal:  Int J Cancer       Date:  2003-07-10       Impact factor: 7.396

8.  IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

Authors:  I Tamm; Y Wang; E Sausville; D A Scudiero; N Vigna; T Oltersdorf; J C Reed
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

9.  The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.

Authors:  Yasushi Takahama; Yukishige Yamada; Koji Emoto; Heisuke Fujimoto; Tomoyoshi Takayama; Masatoh Ueno; Hideki Uchida; Shuya Hirao; Takashi Mizuno; Yoshiyuki Nakajima
Journal:  Gastric Cancer       Date:  2002       Impact factor: 7.370

10.  Expression of survivin, a novel inhibitor of apoptosis and cell cycle regulatory protein, in pancreatic adenocarcinoma.

Authors:  A I Sarela; C S Verbeke; J Ramsdale; C L Davies; A F Markham; P J Guillou
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

View more
  18 in total

1.  Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: evidence from meta-analysis.

Authors:  Jing Tong; Ran Ao; Ying Wang; Bing Chang; Bing-Yuan Wang
Journal:  Int J Clin Exp Med       Date:  2014-09-15

2.  Silibinin exerts sustained growth suppressive effect against human colon carcinoma SW480 xenograft by targeting multiple signaling molecules.

Authors:  Balaiya Velmurugan; Subhash Chander Gangar; Manjinder Kaur; Alpna Tyagi; Gagan Deep; Rajesh Agarwal
Journal:  Pharm Res       Date:  2010-07-14       Impact factor: 4.200

3.  Prognostic value of serum soluble Fas in patients with locally advanced unresectable rectal cancer receiving concurrent chemoradiotherapy.

Authors:  Qi-lian Liang; Zhou-yu Li; Guo-qiang Chen; Zhen-nan Lai; Bi-rong Wang; Jie Huang
Journal:  J Zhejiang Univ Sci B       Date:  2010-12       Impact factor: 3.066

4.  Aberrant expression and function of death receptor-3 and death decoy receptor-3 in human cancer.

Authors:  Zhicheng Ge; Andrew J Sanders; Lin Ye; Wen G Jiang
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

5.  DcR3 promotes proliferation and invasion of pancreatic cancer via a DcR3/STAT1/IRF1 feedback loop.

Authors:  Yijun Wei; Xingyu Chen; Jian Yang; Jun Yao; Ni Yin; Zixiang Zhang; Dechun Li; Dongming Zhu; Jian Zhou
Journal:  Am J Cancer Res       Date:  2019-12-01       Impact factor: 6.166

6.  p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells.

Authors:  Xia Wang; Wei Gong; Haitao Qing; Yan Geng; Xinying Wang; Yongsheng Zhang; Liang Peng; Hongquan Zhang; Bo Jiang
Journal:  Tumour Biol       Date:  2010-06-22

7.  Integrative analysis of TNFRSF6B as a potential therapeutic target for pancreatic cancer.

Authors:  Chen Zhang; Haoran Li; Yujie Huang; Yuchen Tang; Jie Wang; Yinxiang Cheng; Yijun Wei; Dongming Zhu; Zhifei Cao; Jian Zhou
Journal:  J Gastrointest Oncol       Date:  2021-08

8.  Experimental study on Qizhu formula for modulating survivin, an inhibitor of apoptosis, in MGC-803 gastric cancer cells.

Authors:  Hao Wen; Xiaohua Wang; Zhaowei Shan
Journal:  Mol Clin Oncol       Date:  2014-03-13

9.  The expression and clinical significance of PI3K, pAkt and VEGF in colon cancer.

Authors:  Yinxu Zhang; Xiaomei Liu; Junhua Zhang; Leiyu Li; Chunying Liu
Journal:  Oncol Lett       Date:  2012-07-25       Impact factor: 2.967

10.  Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression.

Authors:  Wei Wang; Xinfeng Li; Weimin Sun; Lurong Zhang; Mei Zhang; Benzu Hong; Guorong Lv
Journal:  J Cancer Res Clin Oncol       Date:  2012-05-13       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.